Skip to main content
BCAB
NASDAQ Life Sciences

Shareholders Approve 1-for-50 Reverse Stock Split; Executives Get Large Retention Bonuses Tied to Capital Raising

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.175
Mkt Cap
$12.625M
52W Low
$0.13
52W High
$1.43
52W Position info
35% above low
Off High info
88% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BCAB sits 35% above its 52-week low of $0.13 on light trading volume (0.1× avg).

Summary

Shareholders approved a 1-for-50 reverse stock split, a move typically aimed at preventing delisting, while key executives received significant retention bonuses contingent on achieving financial and capital raising milestones.


Key Events · Financing and Capital Events · BCAB

  • Shareholders Approve 1-for-50 Reverse Stock Split

    At a reconvened special meeting on March 23, 2026, shareholders approved a merger proposal that includes a 1-for-50 reverse stock split. This action will convert every fifty outstanding shares into one, typically undertaken to boost the per-share price to meet exchange listing requirements and avoid delisting. The effective date will be announced at least two business days prior to implementation.

  • Executives Awarded Significant Retention Bonuses Tied to Capital Raising

    The Compensation Committee approved retention bonuses for CEO Jay M. Short ($449,712), CFO Christian Vasquez ($186,110), and CMO Eric Sievers ($265,315), totaling over $900,000. These bonuses are contingent on achieving specific financial and capital raising milestones by August 2026. This follows a year (2025) with no bonuses and no salary increases for 2026, highlighting the company's critical need for capital.


Analysis · BCAB · Life Sciences

This filing reveals two critical developments for BioAtla, Inc., both pointing to significant financial challenges. The approval of a 1-for-50 reverse stock split by shareholders is a strong indicator of the company's efforts to maintain its stock exchange listing, likely due to a persistently low share price. Reverse splits often precede further stock price declines as they do not address underlying business fundamentals. Concurrently, the company has awarded substantial retention bonuses to its CEO, CFO, and CMO, totaling over $900,000. These bonuses are explicitly tied to achieving 'financial and capital raising milestones,' underscoring the company's urgent need for capital. The context of no bonuses in 2025 and no salary increases for 2026 further emphasizes the precarious financial situation and the critical importance of these capital-raising efforts for the company's future operations.

At the time of this filing, BCAB was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6M. The 52-week trading range was $0.13 to $1.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCAB - Latest Insights

BCAB
Jun 03, 2026, 4:07 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $3.40
Real-time Price: $4.35 info
Change: +$0.950 (+28%) info
Market Cap: $6.779M info
BCAB
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.27
Real-time Price: $4.35 info
Change: +$0.080 (+2%) info
Market Cap: $6.779M info
BCAB
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $4.35 info
Change: +$0.080 (+2%) info
Market Cap: $6.779M info
BCAB
Apr 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.1292
Real-time Price: $4.35 info
Change: +$4.22 (+3,267%) info
Market Cap: $6.779M info
BCAB
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1333
Real-time Price: $4.35 info
Change: +$4.22 (+3,163%) info
Market Cap: $6.779M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.1306
Real-time Price: $4.35 info
Change: +$4.22 (+3,231%) info
Market Cap: $6.779M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1306
Real-time Price: $4.35 info
Change: +$4.22 (+3,231%) info
Market Cap: $6.779M info
BCAB
Mar 23, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1749
Real-time Price: $4.35 info
Change: +$4.18 (+2,387%) info
Market Cap: $6.779M info
BCAB
Mar 02, 2026, 7:42 AM EST
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $0.2316
Real-time Price: $4.35 info
Change: +$4.12 (+1,778%) info
Market Cap: $6.779M info
BCAB
Mar 02, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2316
Real-time Price: $4.35 info
Change: +$4.12 (+1,778%) info
Market Cap: $6.779M info